Biohaven Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Biohaven Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||
| product revenue | 193,954,000 | 123,590,000 | 190,013,000 | 135,740,000 | 92,933,000 | 43,823,000 | 35,114,000 | 17,664,000 | 9,698,000 | 1,151,000 | |||||||||
| collaboration and other revenue | 21,125,000 | 195,262,000 | |||||||||||||||||
| total revenues | 215,079,000 | 318,852,000 | |||||||||||||||||
| operating expenses: | |||||||||||||||||||
| cost of sales | 35,741,000 | 26,342,000 | |||||||||||||||||
| research and development | 218,480,000 | 119,099,000 | 91,137,000 | 85,664,000 | 77,428,000 | 107,111,000 | 73,459,000 | 57,044,000 | 42,425,000 | 56,070,000 | 66,019,000 | 61,674,000 | 175,977,000 | 41,003,000 | 37,958,000 | 47,362,000 | 29,052,000 | 75,579,000 | 10,740,000 |
| selling, general and administrative | 250,455,000 | 227,243,000 | 219,458,000 | 164,511,000 | 170,057,000 | 159,523,000 | 122,387,000 | 119,533,000 | 124,802,000 | 95,601,000 | |||||||||
| total operating expenses | 504,676,000 | 372,684,000 | 310,595,000 | 250,175,000 | 247,485,000 | 266,634,000 | 195,846,000 | 176,577,000 | 167,227,000 | 151,671,000 | 134,989,000 | 90,456,000 | 199,212,000 | 54,465,000 | 48,066,000 | 54,936,000 | 38,116,000 | 83,436,000 | 14,497,000 |
| income from operations | -289,597,000 | -53,832,000 | -156,531,000 | -139,949,000 | -171,891,000 | -235,673,000 | -170,700,000 | -163,157,000 | -160,587,000 | -150,944,000 | -134,989,000 | -90,456,000 | -199,212,000 | -54,465,000 | -48,066,000 | -54,936,000 | -38,116,000 | ||
| yoy | 68.48% | -77.16% | -8.30% | -14.22% | 7.04% | 56.13% | 26.45% | 80.37% | -19.39% | 177.14% | 180.84% | 64.66% | 422.65% | ||||||
| qoq | 437.96% | -65.61% | 11.85% | -18.58% | -27.06% | 38.06% | 4.62% | 1.60% | 6.39% | 11.82% | 49.23% | -54.59% | 265.76% | 13.31% | -12.51% | 44.13% | |||
| operating margin % | |||||||||||||||||||
| other income: | |||||||||||||||||||
| interest expense | -17,114,000 | -17,216,000 | -16,937,000 | -9,047,000 | -7,836,000 | -7,731,000 | -7,801,000 | -4,608,000 | -172,000 | -5,000 | -12,000 | -13,000 | |||||||
| interest expense on mandatorily redeemable preferred shares | -8,077,000 | -7,917,000 | -8,164,000 | -8,144,000 | -8,042,000 | -7,943,000 | |||||||||||||
| interest expense on liability related to sale of future royalties | -18,045,000 | -17,314,000 | -17,110,000 | -15,488,000 | -14,499,000 | -13,508,000 | |||||||||||||
| change in fair value of derivatives | -111,197,000 | 3,604,000 | 760,000 | -1,893,000 | -1,490,000 | -210,000 | -12,250,000 | -1,940,000 | |||||||||||
| gain from equity method investment | 5,261,000 | ||||||||||||||||||
| other income | 2,229,000 | 81,000 | -2,502,000 | -5,000 | -3,051,000 | -1,700,000 | |||||||||||||
| total other income | -152,204,000 | -38,762,000 | -43,953,000 | -34,577,000 | -34,918,000 | -25,831,000 | -42,530,000 | -29,482,000 | -19,689,000 | -21,299,000 | -14,346,000 | -15,388,000 | -11,800,000 | -7,730,000 | -6,490,000 | -6,344,000 | -1,128,000 | ||
| income before benefit from income taxes | -441,801,000 | -92,594,000 | -206,809,000 | -261,504,000 | -213,230,000 | -192,639,000 | -180,276,000 | -172,243,000 | -149,335,000 | -105,844,000 | -211,012,000 | -62,195,000 | -54,556,000 | -61,280,000 | -39,244,000 | ||||
| benefit from income taxes | 84,000 | 24,303,000 | 4,350,000 | 3,824,000 | 4,886,000 | 3,989,000 | 658,000 | 694,000 | -71,000 | 323,000 | 58,000 | 109,000 | 194,000 | 161,000 | 25,000 | 87,000 | 193,000 | ||
| net income | -441,885,000 | -116,897,000 | -199,581,000 | -172,328,000 | -211,159,000 | -265,328,000 | -218,116,000 | -196,628,000 | |||||||||||
| yoy | 109.27% | -55.94% | -8.50% | -12.36% | |||||||||||||||
| qoq | 278.01% | -41.43% | 15.81% | -18.39% | -20.42% | 21.65% | 10.93% | ||||||||||||
| net income margin % | |||||||||||||||||||
| net income attributable to non-controlling interests | 498,000 | 498,000 | |||||||||||||||||
| deemed dividend upon repurchase of preferred shares in consolidated subsidiary | -92,673,000 | ||||||||||||||||||
| net income attributable to common shareholders of biohaven pharmaceutical holding company ltd. | -441,387,000 | -209,072,000 | -54,750,000 | -61,441,000 | -39,269,000 | -85,462,000 | -22,753,000 | ||||||||||||
| net income per share | -6.21 | -2.97 | -3 | -2.63 | -3.23 | -4.27 | -3.64 | -3.27 | -3.08 | -3.07 | -2.87 | -2.04 | -4.67 | -1.41 | -1.33 | -1.53 | -1.01 | -2.32 | -1.74 |
| weighted-average common shares outstanding—basic and diluted | 71,043,693 | 70,332,274 | 64,677,823 | 65,389,574 | 65,112,179 | 62,040,715 | 58,732,415 | 59,677,989 | 58,742,329 | 56,412,439 | 48,489,890 | 52,077,240 | 45,226,434 | 44,242,070 | 39,188,458 | 40,147,735 | 38,942,545 | 36,793,090 | 13,088,861 |
| comprehensive loss: | |||||||||||||||||||
| other comprehensive loss, net of tax | -3,413 | -129 | |||||||||||||||||
| comprehensive loss | -445,298 | -119,222 | -162,261.75 | -172,526 | -211,288 | -265,233 | |||||||||||||
| less: comprehensive loss attributable to non-controlling interests | 498 | 498 | -353 | -512 | -540 | -360 | |||||||||||||
| comprehensive loss attributable to biohaven pharmaceutical holding company ltd. | -444,800 | -118,724 | -161,908.75 | -172,014 | -210,748 | -264,873 | |||||||||||||
| other comprehensive income, net of tax | -2,325 | -58 | -198 | 95 | |||||||||||||||
| cost of goods sold | 35,949,000 | 25,514,000 | 17,339,000 | 12,862,000 | 9,968,000 | 4,244,000 | 3,058,000 | 424,000 | |||||||||||
| gross profit | 154,064,000 | 110,226,000 | 75,594,000 | 30,961,000 | 25,146,000 | 13,420,000 | 6,640,000 | 727,000 | |||||||||||
| yoy | 512.68% | 721.36% | 1038.46% | 4158.73% | |||||||||||||||
| qoq | 39.77% | 45.81% | 144.16% | 23.12% | 87.38% | 102.11% | 813.34% | ||||||||||||
| gross margin % | |||||||||||||||||||
| income before benefit for income taxes | -160,709,750 | -174,526,000 | |||||||||||||||||
| benefit for income taxes | 1,494,000 | -2,198,000 | |||||||||||||||||
| less: net income attributable to non-controlling interests | -398,000 | -512,000 | -540,000 | -360,000 | -380,000 | -1,439,000 | |||||||||||||
| net income attributable to biohaven pharmaceutical holding company ltd. | -199,183,000 | -171,816,000 | -210,619,000 | -264,968,000 | -217,736,000 | -195,189,000 | |||||||||||||
| non-cash interest expense on mandatorily redeemable preferred shares | -7,759,000 | -7,310,000 | -6,993,000 | -5,561,000 | -4,378,000 | -4,378,000 | -3,955,000 | ||||||||||||
| non-cash interest expense on liability related to sale of future royalties | -13,288,000 | -11,955,000 | -11,570,000 | -8,425,000 | -7,308,000 | -7,308,000 | -5,151,000 | -6,813,000 | -5,592,000 | -5,633,000 | -501,000 | ||||||||
| income from equity method investment | -690,000 | -607,000 | -1,485,000 | -1,380,000 | -1,768,000 | -1,993,000 | -1,415,000 | -900,000 | -742,000 | -697,000 | -641,000 | ||||||||
| other | -819,500 | -3,062,000 | -119,000 | -152,000 | 3,000 | 8,000 | -16,000 | -17,000 | -151,000 | -2,000 | 27,000 | ||||||||
| change in fair value of derivative liability | 650,000 | -5,781,000 | -895,000 | -1,717,000 | -1,263,000 | 289,000 | |||||||||||||
| net income and comprehensive loss | -180,934,000 | -172,937,000 | -149,264,000 | -106,167,000 | -211,070,000 | -62,304,000 | -54,750,000 | -61,441,000 | -39,269,000 | ||||||||||
| general and administrative | 68,970,000 | 28,782,000 | 23,235,000 | 13,462,000 | 10,108,000 | 7,574,000 | 9,064,000 | 7,857,000 | 3,757,000 | ||||||||||
| change in fair value of warrant liability | |||||||||||||||||||
| change in fair value of contingent equity liability | |||||||||||||||||||
| accretion of beneficial conversion feature on series a preferred shares |
We provide you with 20 years income statements for Biohaven Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Biohaven Pharmaceuticals stock. Explore the full financial landscape of Biohaven Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Biohaven Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.